The Experts below are selected from a list of 114 Experts worldwide ranked by ideXlab platform

Gang Liu - One of the best experts on this subject based on the ideXlab platform.

  • Genetically Engineered Cell membrane nanovesicles for oncolytic adenovirus delivery a versatile platform for cancer virotherapy
    Nano Letters, 2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches.

  • Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy
    2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches

Xuan Liu - One of the best experts on this subject based on the ideXlab platform.

  • Genetically Engineered Cell membrane nanovesicles for oncolytic adenovirus delivery a versatile platform for cancer virotherapy
    Nano Letters, 2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches.

  • Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy
    2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches

David Piwnicaworms - One of the best experts on this subject based on the ideXlab platform.

  • hyperpolarized 1 13c pyruvate to 1 13c lactate conversion is rate limited by monocarboxylate transporter 1 in the plasma membrane
    Proceedings of the National Academy of Sciences of the United States of America, 2020
    Co-Authors: Yi Rao, Seth T Gammon, Niki M Zacharias, Tracy W Liu, Travis C Salzillo, Jing Wang, Pratip K Bhattacharya, David Piwnicaworms
    Abstract:

    Hyperpolarized [1-13C]pyruvate magnetic resonance spectroscopic imaging (MRSI) is a noninvasive metabolic-imaging modality that probes carbon flux in tissues and infers the state of metabolic reprograming in tumors. Prevailing models attribute elevated hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion rates in aggressive tumors to enhanced glycolytic flux and lactate dehydrogenase A (LDHA) activity (Warburg effect). By contrast, we find by cross-sectional analysis using genetic and pharmacological tools in mechanistic studies applied to well-defined Genetically Engineered Cell lines and tumors that initial hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion rates as well as global conversion were highly dependent on and critically rate-limited by the transmembrane influx of [1-13C]pyruvate mediated predominately by monocarboxylate transporter-1 (MCT1). Specifically, in a Cell-encapsulated alginate bead model, induced short hairpin (shRNA) knockdown or overexpression of MCT1 quantitatively inhibited or enhanced, respectively, unidirectional pyruvate influxes and [1-13C]pyruvate-to-[1-13C]lactate conversion rates, independent of glycolysis or LDHA activity. Similarly, in tumor models in vivo, hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion was highly dependent on and critically rate-limited by the induced transmembrane influx of [1-13C]pyruvate mediated by MCT1. Thus, hyperpolarized [1-13C]pyruvate MRSI measures primarily MCT1-mediated [1-13C]pyruvate transmembrane influx in vivo, not glycolytic flux or LDHA activity, driving a reinterpretation of this maturing new technology during clinical translation. Indeed, Kaplan–Meier survival analysis for patients with pancreatic, renal, lung, and cervical cancers showed that high-level expression of MCT1 correlated with poor overall survival, and only in selected tumors, coincident with LDHA expression. Thus, hyperpolarized [1-13C]pyruvate MRSI provides a noninvasive functional assessment primarily of MCT1 as a clinical biomarker in relevant patient populations.

Chengchao Chu - One of the best experts on this subject based on the ideXlab platform.

  • Genetically Engineered Cell membrane nanovesicles for oncolytic adenovirus delivery a versatile platform for cancer virotherapy
    Nano Letters, 2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches.

  • Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy
    2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches

Chao Liu - One of the best experts on this subject based on the ideXlab platform.

  • Genetically Engineered Cell membrane nanovesicles for oncolytic adenovirus delivery a versatile platform for cancer virotherapy
    Nano Letters, 2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches.

  • Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy
    2019
    Co-Authors: Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, Gang Liu
    Abstract:

    Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA. Therefore, we designed bioEngineered Cell membrane nanovesicles (BCMNs) that harbor targeting ligands to achieve robust antiviral immune shielding and targeting capabilities for oncolytic virotherapy. We employed two distinct biomimetic synthetic approaches: the first is based on in vitro genetic membrane engineering to embed targeting ligands on the Cell membrane, and the second is based on in vivo expression of CRISPR-Engineered targeting ligands on red-blood-Cell membranes. The results indicate that both bioengineering approaches preserve the infectivity and replication capacity of OA in the presence of nAbs, in vitro and in vivo. Notably, OA@BCMNs demonstrated a significant suppression of the induced innate and adaptive immune responses against OA. Enhanced targeting delivery, viral oncolysis, and survival benefits in multiple xenograft models were observed without overt toxicity. These findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer Cell selectivity via biomimetic synthesis approaches